The UPcare Group is now advancing to human trials with George Clinical with trials to begin soon.

UPcare’s human trials are based on their previous pre-clinical and real-world data. Pre-clinical trial results conducted by The Doherty institute in 2020 indicated that compounds used in UPCare’s formulations and products are up to 99.99% effective at inhibiting Sars-Cov-2 infected cells. These results demonstrate that UPcare’s UPplus products have huge potential to prevent infections in the general population and also to help cure patients with COVID-19. It is now critical to conduct the necessary human trials to prove that UPcare’s products are effective against COVID-19.

A successful human trial result will enable the UPcare group to make a submission to the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO). Following this submission, they will be registered for Emergency Use Authorization (EUA) with the FDA and Emergency Use Listing (EUL) with the WHO. This will allow expedited worldwide distribution of UPcare’s formulations and products in the fight against COVID-19.

“We are pleased to have the opportunity to work on another COVID-19 clinical trial, this being our third, and to continue to have the opportunity to contribute to finding a clinical solution to the pandemic,” said George Clinical CEO James Cheong.

Following FDA and TGA regulations, UPcare developed both UPplus KBD Spray and UPplus A Capsules as “antiviral botanical drugs”. These formulations have multiple targets, which can reduce drug resistance, and are TGA-approved as listed medicines for three indications:  respiratory health, immune defense, and throat comfort, all symptoms related to the SARS-CoV-2 virus infection and other illnesses. Moreover, the oral administration of these products enables initiation in an outpatient setting which will help limit direct patient interactions with health care staff and decrease transmission risk.

The UPcare Group is based in Melbourne Australia and are a leader in the discovery of antiviral therapies combating respiratory infections. It was founded by a group of leading scientists and researchers to address the growing concerns and proliferation of viruses and other transmitted illnesses through human respiratory functions.